Protocol Single compound
Tesamorelin
GHRH analog
Stabilized GHRH(1-44) analog used as a laboratory reference for GHRH-receptor research.
Compare side by side →Compared with:Sermorelin vs Tesamorelin
Laboratory reference · in vitro research data
- Research vial sizes
- 10 mg · 20 mg
- Dosing data
- Not listed — reference entry covers vial concentration only.
- Storage
- Powder: 2–8 °C, or −20 °C for longer storage. After mixing with BAC water: 2–8 °C, use within about 4 weeks.
Reconstitution concentrations
Concentration per BAC-water volume; 10 units = 0.1 mL on a U-100 syringe.
| Vial | BAC water | mg/mL | mg per 10 u |
|---|---|---|---|
| 10 mg | 1 mL | 10 | 1 |
| 10 mg | 2 mL | 5 | 0.5 |
| 10 mg | 3 mL | 3.33 | 0.333 |
| 20 mg | 1 mL | 20 | 2 |
| 20 mg | 2 mL | 10 | 1 |
| 20 mg | 3 mL | 6.67 | 0.667 |
Calculate your vial
Draw to
—units
= — mL on a U-100 syringe
- Concentration
- —
- Per unit
- —
- Doses / vial
- —
Research dossier · published literature summary
01
Mechanism of action
Tesamorelin is a synthetic analog of human growth hormone-releasing hormone (GHRH 1-44) with an N-terminal trans-3-hexenoyl modification that improves stability against dipeptidyl peptidase-4 cleavage. It binds GHRH receptors on anterior pituitary somatotrophs, activating Gs/cAMP signaling to stimulate pulsatile endogenous growth hormone release, which in turn raises circulating IGF-1.
Contrast: tesamorelin acts on a pituitary receptor (GHRH-R) systemically; GHK-Cu acts locally via copper delivery and gene-expression modulation.
Compare with GHK-Cu →02
Observed research endpoints
- Reduced visceral adipose tissue (VAT) measured by CT in phase 3 trials in HIV-infected adults with abdominal fat accumulation.
- Increased IGF-1 levels while largely preserving physiological pulsatile GH secretion.
- Reduced hepatic fat fraction in HIV-associated fatty liver studies.
- VAT reductions were not maintained after treatment discontinuation in trial extension phases.
Both report tissue-level endpoints — VAT/liver fat here versus collagen and wound-healing measures for GHK-Cu.
Compare with GHK-Cu →03
Regulatory & safety context
- FDA-approved in 2010 (Egrifta) specifically for reducing excess abdominal fat in HIV-infected adults with lipodystrophy.
- Label notes that long-term cardiovascular benefit and safety have not been established, and it is not indicated for weight loss.
- Use outside the approved indication is investigational.
Tesamorelin has an FDA-approved indication with phase 3 data; GHK-Cu has no drug approval and mainly topical cosmetic human data.
Compare with GHK-Cu →04
Citations
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359–2370.2007-12Phase 3 randomized controlled trialRead paper ↗
- Falutz J, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials. Journal of Clinical Endocrinology & Metabolism. 2010;95(9):4291–4304.2010-09Pooled analysis of two phase 3 RCTsRead paper ↗
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389.2014-07Randomized clinical trialRead paper ↗
- Stanley TL, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821–e830.2019-12Phase 2 randomized double-blind trialRead paper ↗
Keep exploring
Related compounds
Found in these stacks & blends
Head-to-head articles
Where researchers source it
Listings are provided for reference — always verify the latest third-party COA before purchasing.
Medvinci Research
See siteFeatured supplier · third-party tested, COA published per batch
Supplier B
TBDPlaceholder — details coming soon
Supplier C
TBDPlaceholder — details coming soon